PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2011
CASE
AUTH/2410/6/11

AUTH/2410/6/11: Hospital physician complaint about paid rep training event (Onglyza) – no breach on appeal

A physician challenged a Β£300-paid invitation to assess sales reps as β€œunderhand”. Panel initially found disguised promotion and inducement concerns, but the…

2008
CASE
Boehringer Ingelheim

Boehringer Ingelheim Pradaxa website: prescribing information not signposted on first HCP landing page (Clause 4.6)

A GP challenged Pradaxa.co.uk access controls and content. PMCPA found no public advertising and no misleading dose issue, but ruled a breach…

2012
CASE
AUTH/2475/1/12 Johnson

AUTH/2475/1/12: Pfizer v Johnson & Johnson – Nicorette Invisi Patch leavepiece comparisons with varenicline

J&J leavepiece for Nicorette Invisi Patch used tick/cross comparisons vs varenicline and a bar chart from an observational study. PMCPA found misleading…

2011
CASE
AUTH/2456/11/11 Boehringer Ingelheim

AUTH/2456/11/11: GP complaint about Pradaxa e-promotion on doctors.net.uk (No breach)

GP alleged Pradaxa web promotion used relative risk without absolute risk and omitted prescribing info with linked reprints. Panel found absolute rates…

2012
CASE
AUTH/2525/7/12 ProStrakan ⭐ Case of the Week

AUTH/2525/7/12: Clinical Lead Pharmacist v ProStrakan (Abstral) – post-operative use discussion (No breach)

A hospital pharmacist alleged ProStrakan reps discussed Abstral for post-operative urology patients (off-label). Panel found the complaint not proven on balance of…

2012
CASE
Astellas Pharma

Astellas voluntary admission: Vesicare ad exceeded two-page limit in Pulse (Clause 6.3)

Pulse mistakenly printed both a 1-page Vesicare ad and a 2-page bound insert, creating 3 pages of Vesicare advertising. Despite publisher error,…

2012
CASE
AUTH/2538/10/12 AstraZeneca

AUTH/2538/10/12: Ex-employee/Director v AstraZeneca (Seroquel investor presentations) – no breach on appeal

Ex-employee alleged archived investor presentations on AstraZeneca’s website repeated earlier problematic Seroquel weight claims. Panel initially found a breach of undertaking, but…

2013
CASE
AUTH/2587/3/13 Almirall

AUTH/2587/3/13: Anonymous gastroenterology consultant v Almirall (Constella) – no breach over alleged free stock inducement

Complaint alleged an Almirall representative offered free Constella stock as a β€œtrial” to support a formulary application. Panel found the complainant provided…

2013
CASE
AUTH/2641/9/13 Lundbeck

AUTH/2641/9/13: Chief Pharmacist v Lundbeck β€” Cipralex promotional email (no breach)

A chief pharmacist complained about a Lundbeck promotional email for Cipralex sent via a database agency to local prescribers. The Panel found…

2013
CASE
AUTH/2611/6/13 Janssen ⭐ Case of the Week

AUTH/2611/6/13: Anonymous renal nurse v Janssen (Durogesic branded pens in conference delegate bags) – No breach on appeal

A renal nurse complained that Durogesic DTrans branded pens were in BRS 2013 delegate bags. Panel found a breach of Clause 18.3,…

2013
CASE
AUTH/2629/8/13 Menarini

Anonymous v Menarini: Sponsorship of BJMA β€˜scientific meeting’ found mainly social (AUTH/2629/8/13)

Menarini sponsored speakers and an exhibition stand at a BJMA UK meeting. The Panel found the event’s main purpose was social/cultural with…

2013
CASE
AUTH/2645/10/13 Amgen

AUTH/2645/10/13 & AUTH/2647/10/13: Patient v Amgen and GlaxoSmithKline (Prolia) – No breach

A patient complained about Prolia patient information, a German leaflet being supplied, and alleged missing side-effect information and β€œyellow marker/black triangle” issues.…

2015
CASE
Bausch

Bausch & Lomb breached ABPI Code over Pulse β€œQuick Guide” on anaphylaxis: disguised promotion and misleading dose/needle depth claims

A Pulse β€œQuick Guide” funded by Bausch & Lomb was found to resemble independent editorial content and included misleading claims about skin-to-muscle…

2015
CASE
AUTH/2747/1/15 Astellas Pharma Europe

Astellas Pharma Europe: Milan β€˜advisory board’ ruled promotional and not a genuine advisory board (Xtandi/enzalutamide) (AUTH/2747/1/15)

Large Milan meeting billed as an advisory board was ruled not genuine; UK HCPs were paid to attend what was deemed promotional…

2015
CASE
AUTH/2758/5/15 Stirling Anglian ⭐ Case of the Week

AUTH/2758/5/15: Galen v Stirling Anglian β€” CosmoCol abbreviated ad and leavepiece breaches (pack/cost info and missing active ingredients)

MIMS β€œabbreviated” CosmoCol ad included pack size/cost and other claims, so needed prescribing info. Both the ad and a leavepiece failed to…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training